Explore treatment options: https://bit.ly/4rPOrM0
Several therapies are approved to help slow progression or target specific forms of ALS. A care team can help determine which options may be appropriate for each situation.
#ALS #ALSTreatment #Neurology #RareDisease #Bionews #ALSNewsToday
Start with the basics: https://bit.ly/40fh5uj
#ALS #ALSTreatment #ALSawareness #LivingWithALS #CaregiverSupport #RareDisease #PatientSupport #BioNews #ALSNewsToday
The Latest ALS News: Expanded access program for ALS drug MN-166 at 50% enrollment. ALSNewsToday.com
ALS Access Update: https://bit.ly/3MtWLSG
An expanded access program for the experimental therapy MN 166 has reached fifty percent enrollment.
#ALS #ALSNewsToday #Bionews #ALSResearch #ExpandedAccess #ClinicalTrials #ALSTreatment #RareDiseaseNews
The latest ALS news highlights the FDA's discussion on CNM-Au8 for ALS treatment, focusing on neurofilament light chain's impact on survival.
Read this update: https://bit.ly/49Hyikq
New survival linked biomarker data could shape the FDA’s review pathway for CNM-Au8 and signal a shift in how ALS therapies are assessed. What this means for the ALS community is still unfolding.
#ALS #ALSTreatment #ALSNews #ALSNewsToday #Bionews
The Latest ALS News highlights Radicava and Radicava ORS management transfer to a U.S. organization, ensuring patient access.
Understand what this means: https://bit.ly/4jG1I7c
Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.
#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews
Megaphone icon with the text: "Qalsody is designed to reduce a toxic protein linked to faster disease progression in people with SOD1 ALS – One step closer to being covered by public Canadian healthcare systems."
Learn about treatment progress: https://bit.ly/4p1b9z4
A gene targeted therapy for SOD1 related ALS is gaining attention as access decisions move forward. Read more to understand what this therapy does.
#ALS #ALSResearch #SOD1ALS #ALSTreatment #ALSNewsToday #Bionews
Graphic summarizing a study on EKZ-438, a precursor to Eikonizo’s EKZ-102, showing potential benefits for ALS treatment by reducing abnormal protein buildup and improving motor neuron survival.
New ALS Drug in Development: https://bit.ly/47tX2N5
Eikonizo Therapeutics’ experimental oral therapy, EKZ-102, is expected to begin clinical testing in 2026.
#ALSNewsToday #Bionews #ALSResearch #ALSTreatment #EikonizoTherapeutics #NeurodegenerativeDisease #ALSNewsToday
Quote on ALS research: Progress in ALS understanding and therapy design, emphasizing upper motor neurons' role. Illustrated with a researcher and a brain diagram.
Rethinking how ALS is treated: https://bit.ly/48j99O6
Northwestern researcher Hande Ozdinler believes progress in ALS treatment will come from understanding the brain’s role and designing therapies that target the disease’s many moving parts.
#ALS #ALSNewsToday #Bionews #ALSTreatment
#Zydus #neurodegenerativedisease #neuroscience #neurology #neurodegeneration #USFDA #FDA #OrphanDrugDesignation #ODD #Usnoflast #NLRP3inhibitor #ALS #amyotrophiclateralsclerosis #ALStreatment #FDAapproval #ZydusLifesciences #Parkinsonsdisease #MultipleSclerosis
pharmatimes.com/news/zydus-a...
